- 作者：Shasha Zhu ; Li Cao ; Jingai Zhu ; Liping Kong ; Junxia Jin ; Lingmei Qian ; Chun Zhu ; Xiaoshan Hu ; Mengmeng Li ; Xirong Guo ; Shuping Han ; Zhangbin Yu
- 关键词：Maternal serum ; miR-19b ; miR-22 ; miR-29c ; miR-375 ; Biomarker
- 刊名：Clinica Chimica Acta
- 出版年：2013
- 出版时间：23 September, 2013
- 年：2013
- 卷：424
- 期：Complete
- 页码：66-72
- 全文大小：552 K
Background
Congenital heart defects (CHD) are the most common form of malformation during embryonic development. Circulating miRNAs have recently been shown to serve as diagnostic/prognostic biomarkers in patients with cancers. Our current study focused on the altered expression of maternal serum miRNAs and their correlation with fetal CHD.Methodology/principle findings
We systematically performed SOLiD sequencing followed by individual quantitative reverse transcription-polymerase chain reaction (qRT-PCR) assays to identify and validate the expression of maternal serum miRNAs at 18-22 weeks of gestation. Four miRNAs (miR-19b, miR-22, miR-29c and miR-375) were found to be significantly up-regulated in pregnant women with fetal CHD, with an area under the receiver operating characteristic (ROC) curve (AUC) of 0.79, 0.671, 0.767 and 0.693, respectively. Furthermore, the combination of the four miRNAs using multiple logistic regression analysis showed a larger AUC (0.813) that was more efficient for the early detection of fetal CHD.
Conclusions/significance
We identified and validated a class of four maternal serum miRNAs which could act as novel non-invasive biomarkers for the prenatal detection of fetal CHD.